HLS Therapeutics Inc is seeing a positive uptick in its stock price, reflecting investor optimism.
HLS Therapeutics Inc (HLS.TO) has experienced a notable rise of 1.17% in its stock price during the last trading session, closing at CA$4.34. This increase comes amidst steady revenue growth and positive market sentiment towards the company’s product lines, particularly Vascepa.
Investor takeaway: Investors may find HLS Therapeutics appealing as it shows resilience and growth potential, especially in its core products, which are gaining traction in the market.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$128.85M
52W high
$5.76
52W low
$4.00
1W change
-3.06%
Beta
0.86
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 76.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.29
+76.9% Upside
Current Price
C$4.12
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
27.8%
Annualized
90-Day Vol
22.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.45
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.88 | C$3.53 – C$4.27 |
| 60 trading days | C$3.66 | C$3.19 – C$4.19 |
| 90 trading days | C$3.45 | C$2.92 – C$4.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
HLS Therapeutics Inc's stock rises by 1.17% in one day.
With a market cap of CA$137.3 million, HLS Therapeutics is navigating a competitive pharmaceutical landscape while managing its financial metrics.
Bull case
The recent 2% year-over-year revenue growth reported for Q1 2026, along with a significant 15% increase in Vascepa net sales, suggests that HLS Therapeutics is on a positive trajectory. This growth could boost investor confidence and attract more interest in the stock.
Bear case
Despite the positive movement, HLS Therapeutics still faces challenges, including a negative profit margin of -18.46%. Investors should be cautious about the company's overall financial health and market volatility.
Recent Performance Overview
Advertisement
HLS Therapeutics Inc's stock closed at CA$4.34 after a 1.17% increase in the last trading session. This upward movement is a positive sign for investors, especially considering the company's recent revenue growth.
Growth Drivers Behind the Stock Surge
The company's flagship product, Vascepa, has seen a 15% increase in net sales year-over-year, significantly contributing to the overall revenue growth of 2% reported for Q1 2026. This performance indicates that HLS Therapeutics is effectively capitalizing on its market opportunities.
Looking Ahead
As HLS Therapeutics prepares for its upcoming financial results conference call on May 15, 2026, investors will be eager to hear more about the company's strategy moving forward. The focus will likely remain on how it plans to enhance product sales and improve its financial standing.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
